QR678, a hair and skin care company, has announced the appointment of Sridhar Ranganathan to its Board of Advisors.
Sridhar, former Managing Director at Allergan, brings a wealth of expertise in biotechnology, healthcare, and aesthetics, which is expected to significantly bolster QR678’s strategic direction and market penetration.
During his tenure as Managing Director at Allergan India and South Asia, Sridhar played a pivotal role in scaling up Botox over several years, significantly expanding its market presence and transforming it into a leading product in the aesthetics industry. His leadership and strategic vision were instrumental in elevating Botox’s prominence, contributing to Allergan’s strong foothold in the market.
Sridhar is a distinguished figure in the medtech industry, currently being part of the IIT Madras incubated enterprises including HELYXON. His role encompasses driving strategic initiatives and leveraging his extensive experience in sales, marketing, and transformational leadership. Additionally, Sridhar is a member of the Steering Committee of HRD at the Department of Biotechnology, Ministry of Science and Technology, which provides strategic directions in biotechnology education and development. Sridhar is also an IICA-certified Indpendent Director.
Sridhar holds an MBA in General Management from Manipal Academy of Higher Education and a Bachelor’s degree in Mathematics from Vivekananda College.
Indrajit Dutta, Vice President, QR678, said, “We are thrilled to welcome Sridhar to the QR678 Board of Advisors. His exceptional background in medtech and pharmaceuticals, coupled with his strategic vision and leadership, will be invaluable as we continue to advance our innovative hair regrowth therapy. Sridhar’s deep understanding of market dynamics, combined with his ability to steer transformative initiatives, will undoubtedly propel QR678® to new heights in both domestic and international markets.”
Adding further, Sridhar Ranganathan said, “The way QR678 has progressed and its penetration in the hair growth segment is nothing short of phenomenal. What excites me about QR678 is not just its significant impact in India but its potential to revolutionize hair regrowth therapy globally. The rigorous research and academic intensity backing QR678, along with its established place in the market, make it an extraordinary journey to be part of. I look forward to collaborating with the team to support QR678’s strategic goals and further its mission of revolutionizing hair regrowth therapy.”
He also shared his thoughts for doctors and aesthetic practitioners, “For practitioners, understanding QR678 in detail and how it can be integrated into their practice is crucial. Whether used as a monotherapy or in combination with other treatments, QR678 offers a robust solution for managing patients with androgenetic alopecia. I believe it can become an essential tool in every practitioner’s arsenal.”
